Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders.

Recs

0
Player Avatar vanguardtrader (82.67) Submitted: 5/19/2009 11:10:08 AM : Underperform Start Price: $12.55 VNDA Score: +13.27

Don't be fooled by this one. Vnda has a mediocre drug that surprised investors with FDA approval. Even though it is being mixed into a billion dollar market, Vanda has no money and will have to partner and license out its drug. form my experience it will get in the low double digits to high single digits in royalties. Vanda is way over priced at this point.

Featured Broker Partners


Advertisement